Literature DB >> 2834997

Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus.

J C Lin1, Z X Zhang, M C Smith, K Biron, J S Pagano.   

Abstract

We show that the anti-human immunodeficiency virus agent, 3'-azido-3'-deoxythymidine (AZT), which suppresses infectivity and cytopathic effects of human immunodeficiency virus, also effectively inhibits Epstein-Barr virus (EBV) DNA replication. However, AZT has no effect on four other human herpesviruses: cytomegalovirus, varicella-zoster virus, and herpes simplex virus types 1 and 2. The combination of acyclovir and AZT, while it is not synergistic, has an additive effect against EBV replication. AZT may prove to be a useful drug for treatment of coinfections with human immunodeficiency virus and EBV.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2834997      PMCID： PMC172149          DOI： 10.1128/AAC.32.2.265

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Cellular transformation by the herpesviruses and antiviral drugs.

Authors:  J C Lin; J S Pagano
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

2.  In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.

Authors:  L Resnick; P D Markham; K Veren; S Z Salahuddin; R C Gallo
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

3.  Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis.

Authors:  I Ernberg; J Andersson
Journal:  J Gen Virol       Date:  1986-10       Impact factor: 3.891

4.  Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus.

Authors:  J C Lin; D J Nelson; C U Lambe; E I Choi
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Pulmonary disease in children with acquired immune deficiency syndrome and AIDS-related complex.

Authors:  A Rubinstein; R Morecki; B Silverman; M Charytan; B Z Krieger; W Andiman; M N Ziprkowski; H Goldman
Journal:  J Pediatr       Date:  1986-04       Impact factor: 4.406

6.  Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on replication of Epstein-Barr virus in human lymphoblastoid cell lines.

Authors:  J C Lin; M C Smith; E I Choi; E De Clercq; A Verbruggen; J S Pagano
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

7.  Pathogenesis of B cell lymphoma in a patient with AIDS.

Authors:  J E Groopman; J L Sullivan; C Mulder; D Ginsburg; S H Orkin; C J O'Hara; K Falchuk; F Wong-Staal; R C Gallo
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

8.  Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.

Authors:  K L Hartshorn; E G Sandstrom; D Neumeyer; T J Paradis; T C Chou; R T Schooley; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  10 in total

1.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.

Authors:  T Baldeweg; J Catalan; B G Gazzard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

4.  Could antiretrovirals be treating EBV in MS? A case report.

Authors:  Natalia C Drosu; Elazer R Edelman; David E Housman
Journal:  Mult Scler Relat Disord       Date:  2018-02-27       Impact factor: 4.339

Review 5.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion.

Authors:  A Schattner; N Hanuka; B Sarov; I Sarov; Z Handzel; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

8.  Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.

Authors:  Barbara Serafini; Barbara Rosicarelli; Caterina Veroni; Gina Adriana Mazzola; Francesca Aloisi
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

Review 9.  Human immunodeficiency virus and multiple sclerosis: a review of the literature.

Authors:  Maria-Ioanna Stefanou; Markus Krumbholz; Ulf Ziemann; Markus C Kowarik
Journal:  Neurol Res Pract       Date:  2019-08-20

10.  Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India.

Authors:  Ameet N Dravid; Raviraj Gawali; Tarun P Betha; Avadesh K Sharma; Mahenderkumar Medisetty; Kartik Natrajan; Milind M Kulkarni; Chinmay K Saraf; Uma S Mahajan; Sachin D Kore; Niranjan M Rathod; Umakant S Mahajan; Scott L Letendre; Rustom S Wadia; Andrea Calcagno
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.